MEK inhibitor cobimetinib reshapes tumor-fibroblast crosstalk in preclinical anaplastic thyroid carcinoma models
A preclinical study reports that the MEK inhibitor cobimetinib suppressed MAPK signaling, tumor cell invasion and immune-evasive features in anaplastic ...
